Dr. Ammar Yousif, MD
NPI: 1457745531
Total Payments
$17,158
2024 Payments
$4,600
Companies
76
Transactions
782
Medicare Patients
469
Medicare Billing
$91,921
Payment Breakdown by Category
Food & Beverage$14,402 (83.9%)
Education$1,525 (8.9%)
Other$1,231 (7.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,402 | 750 | 83.9% |
| Education | $1,525 | 19 | 8.9% |
| Long term medical supply or device loan | $1,231 | 13 | 7.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,737 | 56 | $0 (2024) |
| Incyte Corporation | $1,007 | 37 | $0 (2024) |
| Janssen Biotech, Inc. | $918.03 | 46 | $0 (2024) |
| Astellas Pharma US Inc | $806.54 | 33 | $0 (2024) |
| Celgene Corporation | $774.41 | 40 | $0 (2024) |
| Amgen Inc. | $729.03 | 38 | $0 (2023) |
| Merck Sharp & Dohme LLC | $623.89 | 28 | $0 (2024) |
| PFIZER INC. | $527.58 | 31 | $0 (2024) |
| Eisai Inc. | $520.61 | 26 | $0 (2024) |
| SOBI, INC | $510.50 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,600 | 215 | Novartis Pharmaceuticals Corporation ($951.71) |
| 2023 | $4,215 | 195 | GlaxoSmithKline, LLC. ($336.59) |
| 2022 | $5,343 | 260 | Novartis Pharmaceuticals Corporation ($523.42) |
| 2021 | $2,138 | 77 | Incyte Corporation ($199.60) |
| 2020 | $140.85 | 7 | Amgen Inc. ($23.68) |
| 2019 | $633.83 | 24 | Incyte Corporation ($130.42) |
| 2018 | $87.28 | 4 | Celgene Corporation ($25.71) |
All Payment Transactions
782 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $8.68 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $28.87 | General |
| 11/06/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $30.50 | General |
| Category: Oncology | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $28.59 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $9.54 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $10.31 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.36 | General |
| Category: Hematology | ||||||
| 10/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $9.58 | General |
| Category: Immunology | ||||||
| 10/14/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $9.30 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/07/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: Oncology | ||||||
| 10/04/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $1.98 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/03/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/02/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $41.55 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Oncology | ||||||
| 09/30/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Food and Beverage | In-kind items and services | $30.72 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $6.80 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $32.78 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: Oncology | ||||||
| 09/24/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 235 | 1,441 | $136,533 | $46,826 |
| 2022 | 7 | 217 | 501 | $123,830 | $42,740 |
| 2021 | 1 | 17 | 17 | $5,763 | $2,356 |
Total Patients
469
Total Services
1,959
Medicare Billing
$91,921
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 90 | 289 | $79,797 | $26,739 | 33.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 14 | 67 | $20,300 | $6,191 | 30.5% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 12 | 54 | $7,560 | $4,057 | 53.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $7,130 | $2,561 | 35.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 28 | 32 | $6,412 | $2,182 | 34.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 32 | $4,693 | $1,663 | 35.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 11 | 56 | $3,591 | $1,130 | 31.5% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 13 | 53 | $3,203 | $1,108 | 34.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 74 | $2,309 | $832.77 | 36.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 12 | 34 | $1,185 | $303.27 | 25.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 11 | 730 | $351.20 | $60.57 | 17.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 100 | 274 | $78,065 | $27,431 | 35.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 13 | 68 | $22,100 | $7,349 | 33.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 41 | 41 | $15,099 | $4,938 | 32.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 18 | 25 | $5,025 | $1,812 | 36.1% |
| 36591 | Collection of blood sample from implanted device | Office | 2022 | 16 | 43 | $2,751 | $909.10 | 33.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 13 | 19 | $604.00 | $208.74 | 34.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 16 | 31 | $186.00 | $91.44 | 49.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $5,763 | $2,356 | 40.9% |
About Dr. Ammar Yousif, MD
Dr. Ammar Yousif, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/26/2015. The National Provider Identifier (NPI) number assigned to this provider is 1457745531.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ammar Yousif, MD has received a total of $17,158 in payments from pharmaceutical and medical device companies, with $4,600 received in 2024. These payments were reported across 782 transactions from 76 companies. The most common payment nature is "Food and Beverage" ($14,402).
As a Medicare-enrolled provider, Yousif has provided services to 469 Medicare beneficiaries, totaling 1,959 services with total Medicare billing of $91,921. Data is available for 3 years (2021–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Las Vegas, NV
- Active Since 03/26/2015
- Last Updated 11/12/2024
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1457745531
Products in Payments
- KISQALI (Drug) $1,132
- KEYTRUDA (Biological) $569.60
- Lenvima (Drug) $520.61
- BRUKINSA (Drug) $452.91
- DOPTELET (Drug) $431.71
- ULTOMIRIS (Biological) $371.67
- OPDIVO (Biological) $369.47
- REBLOZYL (Biological) $347.03
- MONJUVI (Drug) $329.77
- ZEJULA (Drug) $301.06
- LIBTAYO (Biological) $278.28
- JAKAFI (Drug) $277.04
- IMFINZI (Biological) $265.67
- ORGOVYX (Drug) $255.91
- ERLEADA (Drug) $249.64
- Nplate (Biological) $240.60
- IMBRUVICA (Drug) $228.35
- JEVTANA (Drug) $220.05
- Cellsearch (Device) $217.84
- GILOTRIF (Drug) $214.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Las Vegas
Robert Deal, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $192,996
Student in an Organized Health Care Education/Training Program $192,996
Elizabeth Mileti, Do, DO
Student in an Organized Health Care Education/Training Program — Payments: $65,404
Student in an Organized Health Care Education/Training Program $65,404
Sai Kottapalli
Student in an Organized Health Care Education/Training Program — Payments: $42,003
Student in an Organized Health Care Education/Training Program $42,003
Dr. Jordan Shively, D.o, D.O
Student in an Organized Health Care Education/Training Program — Payments: $27,789
Student in an Organized Health Care Education/Training Program $27,789
Ruben Nunez, Dpm, DPM
Student in an Organized Health Care Education/Training Program — Payments: $27,716
Student in an Organized Health Care Education/Training Program $27,716
Julian Hardman, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $22,800
Student in an Organized Health Care Education/Training Program $22,800